Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach
Modern Pathology · 2024-11 · 37 (11) · 100589
DOI: 10.1016/j.modpat.2024.100589 ↗Kurz gefasst
Leitlinie in der Zeitschrift Modern Pathology, 2024-11. Verfasst von Matteo Fassan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, Italy; Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy. El…. Hauptthemen laut MEDLINE: Adenocarcinoma, Biomarkers, Tumor, Claudins, Esophageal Neoplasms. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Claudin-18.2 (CLDN18.2) expression evaluated by immunohistochemistry is a new biomarker for gastric and gastroesophageal junction adenocarcinomas that will soon have market authorization for implementation into routine clinical practice. Despite successful testing in the setting of clinical trials, no specific practical testing guidelines have been proposed. Several preanalytical and analytical variables may interfere with adequate CLDN18.2 staining interpretation; thus, this article provides practical guidance on CLDN18.2 testing and scoring in gastric and gastroesophageal junction adenocarcinomas to identify patients who may respond to targeted therapy with monoclonal antibodies directed against CLDN18.2. Based on available data, moderate to strong (2+/3+) membrane staining in ≥75% of adenocarcinoma cells is the proposed cutoff for clinical use of monoclonal antibody anti-CLDN18.2 (zolbetuximab).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, Italy; Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy. Electronic address: matteo.fassan@unipd.it.
- Department of Genetic Medicine and Services, National Cancer Center Hospital East, Chiba, Japan.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
- Department of Pathology, University-Hospital Schleswig-Holstein (UKSH), Kiel, Germany.
- Discovery Life Sciences Biomarker Services, Kassel, Germany.
Zitieren
APA
Fassan, M., Kuwata, T., Matkowskyj, K. A., Röcken, C., & Rüschoff, J. (2024). Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach. Modern Pathology, 37(11), 100589. https://doi.org/10.1016/j.modpat.2024.100589
Vancouver
Fassan M, Kuwata T, Matkowskyj KA, Röcken C, Rüschoff J. Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach. Modern Pathology. 2024;37(11):100589. doi:10.1016/j.modpat.2024.100589
BibTeX
@article{Fassan2024,
author = {Fassan, Matteo and Kuwata, Takeshi and Matkowskyj, Kristina A and Röcken, Christoph and Rüschoff, Josef},
title = {Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach},
journal = {Modern Pathology},
year = {2024},
volume = {37},
number = {11},
pages = {100589},
doi = {10.1016/j.modpat.2024.100589}
}
EUVIMED